han

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer

European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events…

3 weeks ago

Dstillerys Melinda Han Williams Named to ADWEEKs AI Power 50

Dstillery Chief Data Scientist recognized for AI innovation March 09, 2026 12:52 ET  | Source: Dstillery, Inc. NEW YORK, March…

3 months ago